We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SAN DIEGO, Sept. 12 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) announced today that its stockholders approved the previously announced merger with Infinity...
CAMBRIDGE, Mass., Sept. 11 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. will hold a conference call to discuss the outcome of the proxy vote on the proposed reverse merger between Infinity and...
SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) today announced that its board of directors has approved a 4-to-1 reverse split of its common...
CAMBRIDGE, Mass., Aug. 28 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. today announced that Discovery Partners International, Inc. (NASDAQ:DPII), or DPI, has filed a supplement to the Proxy...
SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) today announced that it has filed a supplement to the joint proxy statement/prospectus dated...
- Alliance to Focus on Novel, Targeted Small Molecule Cancer Therapeutics in Two Key Programs - GAITHERSBURG, Md. and CAMBRIDGE, Mass., Aug. 28 /PRNewswire-FirstCall/ -- MedImmune, Inc...
SAN DIEGO, Aug. 9 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) today announced unaudited financial results for the three and six month periods ended June 30...
CAMBRIDGE, Mass., Aug. 8 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. today announced that the Securities and Exchange Commission (SEC) has declared effective the Form S-4 Registration...
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) today announced that the close of business on Tuesday, August 1, 2006, has been set as the...
- Proprietary, water-soluble inhibitor of Heat shock protein 90 (Hsp90), an important target for molecular cancer therapy - CAMBRIDGE, Mass., July 27 /PRNewswire/ -- Infinity Pharmaceuticals...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions